|
|
Volumn 8, Issue 2, 2009, Pages 99-
|
|
Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
GLYCOSYLATED HEMOGLOBIN;
CARDIOVASCULAR DISEASE;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
METABOLISM;
METHODOLOGY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NOTE;
ORGANIZATION AND MANAGEMENT;
PROFESSIONAL STANDARD;
RISK ASSESSMENT;
UNITED STATES;
CARDIOVASCULAR DISEASES;
CLINICAL TRIALS AS TOPIC;
CLINICAL TRIALS DATA MONITORING COMMITTEES;
DIABETES MELLITUS, TYPE 2;
HEMOGLOBIN A, GLYCOSYLATED;
HUMANS;
HYPOGLYCEMIC AGENTS;
RISK ASSESSMENT;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 59849106842
PISSN: None
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2823 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|